Demographics and baseline characteristics were similar between treatment arms¹

DEMOGRAPHICS AND BASELINE CHARACTERISTICS2

ECOG=Eastern Cooperative Oncology Group; PS=performance status.
*Data not available for one patient in the CYRAMZA plus docetaxel group.
Data not available for one patient in each group.



References:
  1. CYRAMZA (ramucirumab) [package insert]. India, Eli Lilly & Company (India) Pvt. Ltd.
  2. Garon EB, Ciuleanu T-E, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384(9944):665-673.
Top